Clinical characteristics, treatment outcomes, and prognostic factors of Pneumocystis pneumonia in non-HIV-infected patients

References

• Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009;301:2578–2585. doi:10.1001/jama.2009.88019549975
   PubMed Web of Science ®Google Scholar
• Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis. 2011;24:534–544. doi:10.1097/QCO.0b013e32834cac1721986616
   PubMed Web of Science ®Google Scholar
• Nakashima K, Aoshima M, Nakashita T, et al. Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study. J Microbiol Immunol Infect. 2017. doi:10.1016/j.jmii.2017.07.007
   Google Scholar
• Michaels SH, Clark R, Kissinger P. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;339:405–406. doi:10.1056/NEJM1998080633906129696654
   PubMed Web of Science ®Google Scholar
• Kaplan JE, Hanson D, Dworkin MS, et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 1):S5–S14. doi:10.1086/31384310770911
   PubMed Web of Science ®Google Scholar
• Maini R, Henderson KL, Sheridan EA, et al. Increasing pneumocystis pneumonia, England, UK, 2000–2010. Emerg Infect Dis. 2013;19:386–392. doi:10.3201/eid1903.12115123622345
   PubMed Web of Science ®Google Scholar
• Bienvenu AL, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S. Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis. 2016;46:11–17. doi:10.1016/j.ijid.2016.03.01827021532
   PubMed Web of Science ®Google Scholar
• Lee WS, Hsueh PR, Hsieh TC, Chen FL, Ou TY, Jean SS. Caspofungin salvage therapy in Pneumocystis jirovecii pneumonia. J Microbiol Immunol Infect. 2017;50:547–548. doi:10.1016/j.jmii.2016.03.00827094385
   PubMedGoogle Scholar
• Cordonnier C, Cesaro S, Maschmeyer G, et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2379–2385. doi:10.1093/jac/dkw15527550990
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lee J, Cho YJ, et al. Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection. J Infect. 2014;69:88–95. doi:10.1016/j.jinf.2014.02.01524607411
   PubMed Web of Science ®Google Scholar
• Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985–2006. Clin Infect Dis. 2008;46:625–633. doi:10.1086/52677818190281
   PubMed Web of Science ®Google Scholar
• Weng L, Huang X, Chen L, et al. Prognostic factors for severe Pneumocystis jiroveci pneumonia of non-HIV patients in intensive care unit: a bicentric retrospective study. BMC Infect Dis. 2016;16:528. doi:10.1186/s12879-016-1987-z27686235
   PubMed Web of Science ®Google Scholar
• Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect. 2014;47:42–47. doi:10.1016/j.jmii.2012.08.02423063081
   PubMedGoogle Scholar
• Pinlaor S, Mootsikapun P, Pinlaor P, et al. PCR diagnosis of Pneumocystis carinii on sputum and bronchoalveolar lavage samples in immuno-compromised patients. Parasitol Res. 2004;94:213–218. doi:10.1007/s00436-004-1200-y15340838
   PubMed Web of Science ®Google Scholar
• Thomas CF Jr., Limper AH. Pneumocystis pneumonia. N Engl J Me. 2004;350:2487–2498. doi:10.1056/NEJMra032588
   PubMed Web of Science ®Google Scholar
• Chien JY, Liu CJ, Chuang PC, et al. Evaluation of the automated Becton Dickinson MAX real-time PCR platform for detection of Pneumocystis jirovecii. Future Microbiol. 2017;12:29–37. doi:10.2217/fmb-2016-011527936923
   PubMed Web of Science ®Google Scholar
• Fauchier T, Hasseine L, Gari-Toussaint M, Casanova V, Marty PM, Pomares C. Detection of Pneumocystis jirovecii by quantitative PCR to differentiate colonization and pneumonia in immunocompromised HIV-positive and HIV-negative patients. J Clin Microbiol. 2016;54:1487–1495. doi:10.1128/JCM.03174-1527008872
   PubMed Web of Science ®Google Scholar
• Chien JY, Chen YT, Wu SG, Lee JJ, Wang JY, Yu CJ. Treatment outcome of patients with isoniazid mono-resistant tuberculosis. Clin Microbiol Infect. 2015;21:59–68. doi:10.1016/j.cmi.2014.08.00825636929
   PubMed Web of Science ®Google Scholar
• Wang CH, Huang CH, Chang WT, et al. Association between hemoglobin levels and clinical outcomes in adult patients after in-hospital cardiac arrest: a retrospective cohort study. Intern Emerg Med. 2016;11:727–736. doi:10.1007/s11739-015-1386-226758060
   PubMed Web of Science ®Google Scholar
• Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. multicenter AIDS cohort study group. N Engl J Med. 1990;322:161–165. doi:10.1056/NEJM1990011832203041967190
   PubMed Web of Science ®Google Scholar
• McAllister F, Steele C, Zheng M, et al. T cytotoxic-1 CD8+ T cells are effector cells against pneumocystis in mice. J Immunol. 2004;172:1132–1138.14707088
   PubMed Web of Science ®Google Scholar
• Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California collaborative treatment group. N Engl J Med. 1990;323:1451–1457. doi:10.1056/NEJM1990112232321042233917
   PubMed Web of Science ®Google Scholar
• Delclaux C, Zahar JR, Amraoui G, et al. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients. Clin Infect Dis. 1999;29:670–672.10530464
   PubMed Web of Science ®Google Scholar
• Lemiale V, Debrumetz A, Delannoy A, Alberti C, Azoulay E. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res. 2013;14:87. doi:10.1186/1465-9921-14-1923981859
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, Helweg-Larsen J, Pagano L, et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. J Antimicrob Chemother. 2016;71:2405–2413. doi:10.1093/jac/dkw15827550993
   PubMed Web of Science ®Google Scholar
• Ruan SY, Lin HH, Huang CT, Kuo PH, Wu HD, Yu CJ. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2014;18:R63. doi:10.1186/cc1371224708846
   PubMed Web of Science ®Google Scholar
• Festic E, Gajic O, Limper AH, Aksamit TR. Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest. 2005;128:573–579. doi:10.1378/chest.128.2.57316100140
   PubMed Web of Science ®Google Scholar
• Yiannakis EP, Boswell TC. Systematic review of outbreaks of Pneumocystis jirovecii pneumonia: evidence that P. jirovecii is a transmissible organism and the implications for healthcare infection control. J Hosp Infect. 2016;93:1–8. doi:10.1016/j.jhin.2016.01.01826996089
   PubMed Web of Science ®Google Scholar